SLC22A17: A Potential Drug Target for Pain, Neuroinflammation and Other Processes

Target Name: SLC22A17

NCBI ID: G51310

SLC22A17

SLC22A17: A Potential Drug Target for Pain, Neuroinflammation and Other Processes

SLC22A17 is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. It is a member of the sodium channel subfamily 22, which is responsible for the regulation of ion channels in the nervous system.

SLC22A17 has been identified as a potential drug target due to its involvement in several neurological and cardiovascular disorders. One of the main reasons for its potential as a drug target is its involvement in the regulation of pain perception and neuroinflammation.

SLC22A17 has been shown to play a role in the regulation of pain perception. Several studies have shown that SLC22A17 is involved in the regulation of pain perception, with SLC22A17 expressing levels increasing in individuals that report high levels of pain. Additionally, SLC22A17 has been shown to interact with other pain-related molecules, such as TrkA, a G protein-coupled receptor that is involved in pain perception.

SLC22A17 has also been shown to be involved in the regulation of neuroinflammation. Neuroinflammation is a type of inflammation that occurs in the brain and can be caused by a variety of factors, such as trauma, infection, and disease. SLC22A17 has been shown to play a role in the regulation of neuroinflammation by regulating the production of pro-inflammatory molecules.

In addition to its involvement in pain perception and neuroinflammation, SLC22A17 has also been shown to be involved in the regulation of other physiological processes in the body. For example, SLC22A17 has been shown to play a role in the regulation of blood pressure, as has been shown to increase blood pressure in individuals with high blood pressure. Additionally, SLC22A17 has been shown to play a role in the regulation of insulin sensitivity, with SLC22A17 expressing levels increasing in individuals with poorly insulin-sensitive conditions.

Due to its involvement in these processes, SLC22A17 has been identified as a potential drug target. Researchers are currently working to develop compounds that can inhibit SLC22A17 activity and treat a variety of neurological and cardiovascular disorders. These compounds have the potential to become new treatments for a variety of conditions, including pain, neuroinflammation, and cardiovascular disease.

In conclusion, SLC22A17 is a protein that is involved in the regulation of various physiological processes in the body. Its potential as a drug target is due to its involvement in pain perception, neuroinflammation, and other processes in the body. As research continues, the potential of SLC22A17 as a drug target will be further understood, and new treatments for a variety of neurological and cardiovascular disorders may be developed.

Protein Name: Solute Carrier Family 22 Member 17

Functions: Cell surface receptor for LCN2 (24p3) that plays a key role in iron homeostasis and transport. Able to bind iron-bound LCN2 (holo-24p3), followed by internalization of holo-24p3 and release of iron, thereby increasing intracellular iron concentration and leading to inhibition of apoptosis. Also binds iron-free LCN2 (apo-24p3), followed by internalization of apo-24p3 and its association with an intracellular siderophore, leading to iron chelation and iron transfer to the extracellular medium, thereby reducing intracellular iron concentration and resulting in apoptosis (By similarity)

The "SLC22A17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets